Motus gi reports first quarter 2023 financial results and provides corporate update

■ oral presentation at the digestive disease week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (ibp)in just six months after implementation of the pure-vu® system at the minneapolis va medical center         ■ the company is advancing its development of pure-vu evs gastro, designed for upper gi bleeding procedures - an area of high unmet patient need - and expects submission of the 510(k) to the fda for this new product line and its next generation lower gi platform in q4 2023         ■ the company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the pure-vu system and maximizing stockholder value fort lauderdale, fla., may 10, 2023 (globe newswire) -- motus gi holdings, inc. (nasdaq: mots) (“motus gi” or the “company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended march 31, 2023, and provided a corporate update.
MOTS Ratings Summary
MOTS Quant Ranking